# NCT05257408 (NCT05257408)

> Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05257408
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Corcept Therapeutics
- Conditions: Ovarian Neoplasm; Fallopian Tube Neoplasms; Peritoneal Neoplasms
- Interventions: Relacorilant 150 mg; Nab-paclitaxel 80 mg/m^2; Nab-paclitaxel 100 mg/m^2
- Enrollment: 381
- Primary outcome: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival

## Commentary we found

- YouTube: 44
- Podcasts: 23
- X threads: 18

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct05257408

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05257408", "email": "<work email>"}; the inbox owner confirms by the emailed link.